ReproCELLorp (FRA:6RC) Total Operating Expense: €10.64 Mil (TTM As of Mar. 2026)


FRA:6RC ReproCELL Incorp FRA:6RC
61 GF Score
Price €0.48
GF Value €0.58
! 3 Warning Signs
View Full Analysis

What is ReproCELLorp Total Operating Expense?

ReproCELLorp FRA:6RC 61 Total Operating Expense is €10.64 Mil as of Mar. 2026. GuruFocus rates FRA:6RC with a GF Score™ of 61/100 and a GF Value™ of €0.58. The stock has 3 warning signs investors should review.

ReproCELLorp's Total Operating Expense for the three months ended in Mar. 2026 was €2.65 Mil. ReproCELLorp's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €10.64 Mil.

ReproCELLorp Total Operating Expense Related Terms

ReproCELLorp Total Operating Expense Historical Data

* Premium members only.

The historical data trend for ReproCELLorp's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ReproCELLorp Total Operating Expense Chart

ReproCELLorp Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.11 10.46 9.40 11.04 10.22

ReproCELLorp Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.98 2.91 2.58 2.50 2.65
FRA:6RC
61GF Score
ReproCELL Incorp FRA:6RC
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ReproCELLorp Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €10.64 Mil mean?
ReproCELLorp (FRA:6RC) has a Total Operating Expense of €10.64 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on ReproCELLorp and its competitors.
Is ReproCELLorp's Total Operating Expense too high?
ReproCELLorp's current Total Operating Expense is €10.64 Mil. Overall, ReproCELLorp has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does ReproCELLorp's Total Operating Expense compare to VRTX and REGN?
ReproCELLorp's Total Operating Expense of €10.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on ReproCELLorp and its competitors. ReproCELLorp's current Total Operating Expense is €10.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ReproCELLorp stock overvalued right now?
ReproCELLorp (FRA:6RC) has a current Total Operating Expense of €10.64 Mil. The stock's GF Value™ is €0.58, compared to a current price of €0.48 — trading 17.2% below its estimated fair value. The current Total Operating Expense is €10.64 Mil. ReproCELLorp's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For ReproCELLorp (FRA:6RC), the current Total Operating Expense is €10.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ReproCELLorp (FRA:6RC) Overvalued in 2026?

Based on GuruFocus' analysis, ReproCELLorp stock appears to be undervalued. The current stock price of €0.48 is trading 17.2% below its estimated GF Value™ of €0.58.

Key valuation signals for FRA:6RC:

  • Total Operating Expense: €10.64 Mil
  • GF Value™: €0.58 vs. price of €0.48 (17.2% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the FRA:6RC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ReproCELLorp Business Description

Other Exchanges 4978:Japan
Address KDX Shin-Yokohama 381 Bldg. 9F, 3-8-11, Shin-Yokohama, Kohoku-ku, Kanagawa, Yokohama, JPN, 222-0033
ReproCELL Incorp is one of the leading stem cell research company in Japan. The company provides stem cell services, predictive drug discovery services, tissue services, and molecular services.
61GF Score

Get the complete analysis for FRA:6RC

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price
€0.58
GF Value